Search

Displaying results 4381 - 4390 of 5897 in total
  1. Drug

    MBL-HCV1

    go.drugbank.com/drugs/DB17776
    Investigational

    MBL-HCV1 is a monoclonal antibody developed to prevent the recurrence of hepatitis C virus (HCV) in patients receiving a liver transplant.

  2. Drug

    Eltrekibart

    go.drugbank.com/drugs/DB19017
    Investigational

    Eltrekibart is under investigation in clinical trial NCT06046729 (A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa).

  3. Drug

    Tebapivat

    go.drugbank.com/drugs/DB19338
    Investigational

    Tebapivat is under investigation in clinical trial NCT05490446 (A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-risk Myelodysplastic Syndromes (LR-MDS)).

    Synonyms: 6-[(6-aminopyridin-2-yl)methyl]-4-methyl-2-[(1H-pyrazol-3-yl)methyl]-4,6-dihydro-5H-[1,3]thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
  4. Drug

    Topsalysin

    go.drugbank.com/drugs/DB05160
    Investigational

    Topsalysin is delivered locally to the prostate under ultrasound guidance.

  5. Drug

    Norgestomet

    go.drugbank.com/drugs/DB11440
    InvestigationalVet approved

    Norgestomet, also known as 11β-methyl-17-hydroxy-19-norprogesterone acetate, is a steroidal progestin used in veterinary medicine to control estrus and ovulation in cattle.

  6. Drug

    Furaprevir

    go.drugbank.com/drugs/DB12785
    Investigational

    Furaprevir is under investigation in clinical trial NCT01523990 (A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients).

  7. Drug

    Neihulizumab

    go.drugbank.com/drugs/DB16698
    Investigational

    Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.[L34450]

  8. Drug

    MB-102 CD123 CAR

    go.drugbank.com/drugs/DB17366
    Investigational

    MB-102 are autologous T cells genetically modified to express CD123-specific, hinge-optimized CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor.

  9. Drug

    WU-CART-007

    go.drugbank.com/drugs/DB18617
    Investigational

    WU-CART-007 consists of allogeneic, fratricide-resistant genetically modified T cells transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7.

  10. Drug

    Danicamtiv

    go.drugbank.com/drugs/DB18962
    Investigational

    Danicamtiv is under investigation in clinical trial NCT04572893 (Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities).